Holen Sie sich die Stockscreener-App
27.64
19.18%
-6.56
Handel nachbörslich:
28.19
0.55
+1.99%
Schlusskurs vom Vortag:
$34.20
Offen:
$31.15
24-Stunden-Volumen:
305.08K
Relative Volume:
2.17
Marktkapitalisierung:
$188.68M
Einnahmen:
$32.73M
Nettoeinkommen (Verlust:
$-19.52M
KGV:
-5.0005
EPS:
-5.5275
Netto-Cashflow:
$-24.61M
1W Leistung:
+5.90%
1M Leistung:
-11.30%
6M Leistung:
+216.50%
1J Leistung:
+11.54%
1-Tages-Spanne:
$27.38
$34.19
1-Wochen-Bereich:
$24.94
$34.60
52-Wochen-Spanne:
$4.971
$45.50
Cue Biopharma Inc Stock (CUE) Company Profile
Firmenname
Cue Biopharma Inc
Sektor
Branche
Telefon
617-949-2680
Adresse
40 GUEST STREET, BOSTON, MA
Compare CUE vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
27.64 | 233.46M | 32.73M | -19.52M | -24.61M | -5.5275 |
VRTX
Vertex Pharmaceuticals Inc
|
515.55 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.93 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
987.84 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.00 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.51 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-03-13 | Eingeleitet | Jefferies | Buy |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-11-21 | Eingeleitet | Piper Sandler | Overweight |
| 2022-01-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-01-03 | Eingeleitet | Craig Hallum | Buy |
| 2020-11-24 | Eingeleitet | Berenberg | Buy |
| 2020-04-09 | Eingeleitet | Stifel | Buy |
| 2020-01-28 | Eingeleitet | BTIG Research | Buy |
| 2020-01-22 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Cue Biopharma Inc Aktie (CUE) Neueste Nachrichten
Cue Biopharma (CUE) Q2 Results Highlight High Price-to-Sales Ami - GuruFocus
CUE Stock Jumps Over 100% After Hours — What’s Driving The Rally? - Stocktwits
Cue Biopharma (NASDAQ:CUE) Lowered to "Hold" Rating by Wall Street Zen - MarketBeat
Cue Biopharma CEO Lin sells shares worth $1.6 million - Investing.com
Cue Biopharma CEO Lin sells shares worth $1.6 million By Investing.com - Investing.com Nigeria
Insider Selling: Cue Biopharma (NASDAQ:CUE) CEO Sells $1,084,000.00 in Stock - MarketBeat
Insider Selling: Cue Biopharma (NASDAQ:CUE) CEO Sells 18,258 Shares - MarketBeat
Insider plans 58,258-share stock sale (NASDAQ: CUE) under Rule 144 - Stock Titan
Cue Biopharma (NASDAQ:CUE) Posts Quarterly Earnings Results, Misses Estimates By $22.45 EPS - MarketBeat
Cue Biopharma, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Cue Biopharma Q2 Results: EPS Loss Widens to $24.14 Despite Sales Beat - scanx.trade
Is Cue Biopharma Inc (CUE) Facing Financial Strain After Q2 Loss - GuruFocus
Cue Biopharma Q2 revenue more than doubles, net loss widens on one-time charges - TradingView
Cue Biopharma Raises $50M for CUE-221 Food Allergy Program - Stock Titan
Cue Biopharma Stock (CUE) Opinions on Management Changes and Phase 2 Data Prospects - Quiver Quantitative
Driehaus Capital discloses 6.96% Cue Biopharma (CUE) holding in Schedule 13G - Stock Titan
Cue Biopharma Inc. (NASDAQ: CUE)Dividends - intelligentinvestor.com.au
Cue Biopharma, Inc. SEC Filing (Aug 14, 2026) - Stock Titan
Cue Biopharma (CUE) registers 1.51M shares for stockholder resale after $50M raise - Stock Titan
Cue Biopharma (CUE) Expected to Announce Earnings on Tuesday - MarketBeat
Cue Biopharma (NASDAQ:CUE) Trading Down 3.8%Should You Sell? - MarketBeat
Cue Biopharma (CUE) Holds Steady Near $27 as Biotech Sector Digests MomentumEMA Signal - dars.gov.et
CUE Stock On Track For Best Day In History — Why Is Retail Optimistic? - Stocktwits
Cue Biopharma, Inc. expected to post a loss of $1.69 a shareEarnings Preview - TradingView
Cue Biopharma Inc (CUE) Stock News Today - TradingKey
Cue Biopharma Inc (CUE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cue Biopharma Appoints Veteran James Ahlers as CFO - The Globe and Mail
Cue Biopharma Appoints James Ahlers as Chief Financial Officer – SEC 8-K Filing Details - Minichart
Cue appoints James Ahlers as Chief Financial Officer - TradingView
Cue Biopharma (CUE) hires James Ahlers as CFO with equity and severance package - Stock Titan
Cue Biopharma, Inc. Announces Appointment of James Ahlers as Principal Financial Officer, Effective July 30, 2026 - marketscreener.com
Cue Biopharma names James Ahlers as chief financial officer By Investing.com - Investing.com Nigeria
Cue Biopharma Names James Ahlers CFO - Moomoo
Cue Biopharma names James Ahlers as chief financial officer - Investing.com
Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission - Yahoo Finance
Cue Biopharma appoints James M. Ahlers as CFO to steer clinical-stage growth - scanx.trade
Cue Biopharma Inc (CUE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CUE|Cue Biopharma Inc|Price:32.120|Chg%:-0.970 - TradingKey
Cue Biopharma Inc (CUE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cue Biopharma Company Profile & Introduction - Moomoo
Enterprise value to EBITDA forward of Cue Biopharma, Inc. – NASDAQ:CUE - TradingView
Cue Biopharma Inc (CUE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cue Biopharma Inc (CUE) Income Statement - TradingKey
Cue Biopharma Inc (CUE) Balance Sheet - TradingKey
Cue Biopharma, Inc. Revenue Breakdown – NASDAQ:CUE - TradingView
Cue Biopharma Inc (CUE) Cash Flow - TradingKey
Cue Biopharma Inc (CUE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Enterprise value to EBITDA forward of Cue Biopharma, Inc. – DUS:1UC0 - TradingView
Cue Biopharma (CUE) Stock Forecast & Analyst Ratings - Moomoo
Cue Biopharma, Inc. announced that it has received $49.999926 million in funding from Cormorant Asset Management, LP, Threadneedle Asset Management Limited - marketscreener.com
Cue Biopharma (CUE) completes $49,999,927 Reg D Rule 506(b) raise - Stock Titan
Finanzdaten der Cue Biopharma Inc-Aktie (CUE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cue Biopharma Inc-Aktie (CUE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lin Shao-Lee | Chief Executive Officer |
Aug 12 '26 |
Sale |
27.10 |
40,000 |
1,083,989 |
724,253 |
| Lin Shao-Lee | Chief Executive Officer |
Aug 13 '26 |
Sale |
28.62 |
18,258 |
522,573 |
705,995 |
1.80%
1.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):